15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs

ABIM Critical Care Medicine Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Orientation: Format, Blueprint & Study Strategy

1.1 ABIM Critical Care Medicine Exam: Format, Blueprint & Study Strategy

2 Chapter 2: Acute Respiratory Failure & ARDS

2.1 ARDS Definition, Pathophysiology & Phenotypes 2.2 Lung-Protective Mechanical Ventilation 2.3 Refractory ARDS: Prone Positioning, Neuromuscular Blockade & VV-ECMO

3 Chapter 3: Obstructive Airways, Pulmonary Vascular & Pleural Emergencies

3.1 Severe Asthma & COPD Exacerbations in the ICU 3.2 Massive & Submassive Pulmonary Embolism 3.3 Pulmonary Hypertension & Right Ventricular Failure in the ICU 3.4 Massive Hemoptysis, Complex Pleural Effusions & Thoracic Drainage

4 Chapter 4: Airway, Parenchymal & Nonthrombotic Pulmonary Emergencies

4.1 Airway Management, Upper-Airway Obstruction & Artificial-Airway Complications 4.2 Diffuse Alveolar Hemorrhage, Interstitial Lung Disease, Pulmonary Vasculitis & Noncardiogenic Edema 4.3 Severe Community-Acquired & Viral Pneumonia 4.4 Nonthrombotic Embolism (Air, Fat, Amniotic Fluid, Tumor, Septic) & Acute Chest Syndrome

5 Chapter 5: Mechanical Ventilation Modes, Dyssynchrony & Liberation

5.1 Mechanical Ventilator Modes & Advanced Breath Delivery 5.2 Patient-Ventilator Dyssynchrony & Waveform Analysis 5.3 Ventilator Liberation, Spontaneous Breathing Trials & Post-Extubation Support

6 Chapter 6: Shock Syndromes & Hemodynamic Principles

6.1 Shock Classification, Cellular Pathophysiology & Biomarkers 6.2 Hemodynamic Monitoring: Arterial Lines, CVP & Pulmonary Artery Catheter 6.3 Dynamic Assessment of Fluid Responsiveness & Resuscitation Targets

7 Chapter 7: Vasoactive Therapies & Mechanical Circulatory Support

7.1 Vasopressors & Inotropes: Pharmacology & Clinical Titration 7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart 7.3 Venoarterial ECMO (VA-ECMO) & Differential Hypoxemia 7.4 Post-Cardiac Arrest Care, Targeted Temperature Management & Neuroprognostication

8 Chapter 8: Acute Kidney Injury & Renal Replacement Therapy

8.1 KDIGO AKI Classification, Etiologies & Diagnostic Evaluation 8.2 Continuous Renal Replacement Therapy (CRRT) vs Intermittent Hemodialysis 8.3 Indications & Timing for RRT in Critical Illness: AKIKI & STARRT-AKI

9 Chapter 9: Electrolyte, Acid-Base & Endocrine Emergencies

9.1 Severe Dysnatremias: Hyponatremia, Hypernatremia & Osmotic Demyelination 9.2 Potassium, Calcium, Magnesium & Phosphate Disorders 9.3 Complex & Mixed Acid-Base Disorders: Boston vs Copenhagen vs Stewart 9.4 Endocrine Crises: DKA, HHS, Thyroid Storm, Myxedema Coma & Adrenal Crisis

10 Chapter 10: Glycemic Control, Hyperammonemia, Pituitary & Adrenal Disorders

10.1 ICU Glycemic Control & Severe Hypoglycemia 10.2 Non-Hepatic Hyperammonemia & Metabolic Encephalopathy 10.3 Pituitary Emergencies, Adrenal Excess & Critical Illness-Related Corticosteroid Insufficiency

11 Chapter 11: Acute Coronary Syndromes & Cardiac Arrhythmias

11.1 Acute Coronary Syndromes & Mechanical Complications of Myocardial Infarction 11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF 11.3 Critical Bradyarrhythmias, Conduction Blocks & Temporary Cardiac Pacing

12 Chapter 12: Acute Heart Failure, Valvular & Pericardial Emergencies

12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies 12.3 Pericardial Tamponade & Acute Aortic Syndromes

13 Chapter 13: Myocardial Disease, Hypertensive & Cardiac Device Emergencies

13.1 Fulminant Myocarditis, Stress & Peripartum Cardiomyopathy, and Hypertrophic Cardiomyopathy 13.2 Hypertensive Emergencies & Ruptured Abdominal Aortic Aneurysm 13.3 Implanted Cardiac Devices, LVAD Emergencies & Electrical Storm

14 Chapter 14: Sepsis & Systemic Infectious Diseases

14.1 Sepsis-3 Definitions & Surviving Sepsis Campaign 2026 Guidelines 14.2 Refractory Septic Shock & Adjunctive Therapies 14.3 Multidrug-Resistant Pathogens & Antimicrobial Stewardship in the ICU

15 Chapter 15: ICU-Acquired & Severe Focal Infections

15.1 Hospital-Acquired & Ventilator-Associated Pneumonia 15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs 15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections

16 Chapter 16: Focal, Special-Host & Systemic Infections

16.1 CNS Infections Beyond Bacterial Meningitis: Encephalitis, Brain Abscess & Epidural Abscess 16.2 Infections in the Immunocompromised Host, Tropical & Bioterror Infections 16.3 Infective Endocarditis, Device Infections & Other Focal Cardiovascular Infections 16.4 Antimicrobial Pharmacokinetics, Allergy, Toxicity & Infection Prevention 16.5 Gastrointestinal & Hepatobiliary Infections: Fulminant C. difficile, Typhlitis, CMV Colitis & Abscesses

17 Chapter 17: Neurocritical Care & Coma

17.1 Coma, Altered Mental Status & Acute Delirium in the ICU 17.2 Status Epilepticus & Non-Convulsive Status Epilepticus 17.3 Acute Ischemic Stroke & Intracranial Hemorrhage

18 Chapter 18: Cerebrovascular Syndromes, Encephalopathy & Withdrawal States

18.1 Cerebral Venous Sinus Thrombosis, PRES & Reversible Cerebral Vasoconstriction Syndrome 18.2 Alcohol & Sedative Withdrawal, Wernicke Encephalopathy & Drug-Induced Encephalopathy

19 Chapter 19: Intracranial Hypertension & Neuromuscular Weakness

19.1 Intracranial Pressure Monitoring, Cerebral Perfusion & Tiered ICP Management 19.2 Acute Neuromuscular Respiratory Failure, ICU-Acquired Weakness & Brain Death Determination

20 Chapter 20: Traumatic Brain Injury, Spinal Cord Injury & Toxin-Mediated Paralysis

20.1 Traumatic Brain Injury Management & Paroxysmal Sympathetic Hyperactivity 20.2 Acute Spinal Cord Injury, Neurogenic Shock & Autonomic Dysreflexia 20.3 Toxin-Mediated Paralysis & Neuromuscular Crises: Botulism, Tetanus, Tick Paralysis & Myasthenic Crisis

21 Chapter 21: Gastrointestinal, Hepatic & Abdominal Emergencies

21.1 Acute Upper & Lower Gastrointestinal Bleeding in the ICU 21.2 Acute Liver Failure & Severe Acute Pancreatitis 21.3 Abdominal Compartment Syndrome & Acute Mesenteric Ischemia

22 Chapter 22: Luminal GI Emergencies & Complications of Cirrhosis

22.1 Esophageal, Gastric & Bowel Emergencies: Perforation, Obstruction, Ogilvie Syndrome & Colonic Ischemia 22.2 Complications of Cirrhosis: Alcohol-Associated Hepatitis, Hepatorenal Syndrome & Pulmonary Vascular Syndromes

23 Chapter 23: Trauma, Burns & Perioperative Critical Care

23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion 23.2 Severe Burn Injury, Inhalation Injury & Environmental Emergencies 23.3 Perioperative Critical Care for High-Risk Surgical Patients

24 Chapter 24: Thoracic Trauma, Environmental Injury & Obstetric Critical Care

24.1 Thoracic Trauma: Flail Chest, Pulmonary Contusion, Great Vessel & Tracheobronchial Injury 24.2 Environmental Injury: Drowning, Diving, Altitude, Heat, Cold, Electrical & Radiation 24.3 Obstetric & Genitourinary Emergencies and the Physiology of Pregnancy

25 Chapter 25: Transplantation, Donor Management & Post-Cardiac Surgery Care

25.1 Solid Organ Transplant Recipients & Deceased Donor Management 25.2 Post-Cardiac Surgery Critical Care: Bleeding, Tamponade, Low Output & Vasoplegia

26 Chapter 26: Hematologic Emergencies, Toxicology, Critical Ultrasound & ICU Liberation

26.1 Hematologic Emergencies in the ICU: HIT, DIC, TMA & Anticoagulant Reversal 26.2 Critical Care Toxicology, Toxidromes & Specific Antidotes 26.3 Critical Care Point-of-Care Ultrasound (POCUS) 26.4 ICU Liberation, Analgosedation, Goals of Care & Critical Care Ethics

27 Chapter 27: Transfusion Medicine, Hematologic & Oncologic Disorders

27.1 Transfusion Medicine: Products, Thresholds, Reactions & Apheresis 27.2 Red and White Cell Disorders, Hemoglobinopathies, Factor Deficiencies & Hypercoagulable States 27.3 Oncologic Emergencies, Hematopoietic Cell Transplant Complications & Cellular Therapy Toxicity

28 Chapter 28: Clinical Pharmacology, Adverse Drug Reactions & Specific Poisonings

28.1 Pharmacokinetic Principles, Dose Adjustment & Drug Interactions in Critical Illness 28.2 Adverse Drug Reactions: Anaphylaxis, Severe Cutaneous Reactions & Hyperthermic Syndromes 28.3 Specific Poisonings: Sodium-Channel Blockers, Lithium, Valproate, Theophylline, Iron, Sulfonylureas & Methemoglobinemia

29 Chapter 29: Ethics, Research Methods, Administration & Abdominal Ultrasound

29.1 Advance Care Planning, Nonbeneficial Treatment, Informed Consent & Confidentiality 29.2 Critical Care Research Methods, Statistics, IRB Oversight & Quality Improvement 29.3 Abdominal, Vascular & Procedural Point-of-Care Ultrasound

15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs

Key Takeaways Explain This Topic AI

Central line-associated bloodstream infection (CLABSI) is a surveillance definition requiring an intravascular line in place for > 2 > 2 > 2 calendar days and a laboratory-confirmed bloodstream infection without alternative source.

Catheter-related bloodstream infection (CRBSI) is clinically confirmed in situ by a differential time to positivity (DTP) ≥ 2 hours \ge 2\text{ hours} ≥ 2 hours (catheter blood culture flagging positive at least 2 hours before peripheral blood culture) or a quantitative catheter-to-peripheral ratio ≥ 3 : 1 \ge 3:1 ≥ 3 : 1 .

Immediate catheter removal is mandatory for bacteremia or fungemia caused by Staphylococcus aureus, Candida species, Pseudomonas aeruginosa, multidrug-resistant Gram-negatives, or in the presence of tunnel infection, septic thrombophlebitis, or septic shock.

All patients with S. aureus bacteremia (SAB) require mandatory echocardiography (preferably TEE) and serial blood cultures until clearance, with targeted IV therapy duration of at least 14 days for uncomplicated and 4 to 6 weeks for complicated SAB.

Catheter-associated UTI (CAUTI) requires compatible clinical signs or symptoms plus ≥ 10 3 CFU/mL \ge 10^3\text{ CFU/mL} ≥ 1 0 3 CFU/mL of bacterial growth; asymptomatic bacteriuria (ASB) in catheterized patients must NOT be treated with antimicrobials.

Last updated: October 2026

Diagnostic Framework: CLABSI vs. CRBSI

Vascular access is indispensable in the intensive care unit for hemodynamic monitoring, vasoactive drug administration, and fluid resuscitation. However, central venous catheters (CVCs) represent the leading source of nosocomial bloodstream infections. Clinicians must understand the distinct operational and clinical definitions:

Central Line-Associated Bloodstream Infection (CLABSI) : A public health and epidemiological surveillance definition established by the CDC National Healthcare Safety Network (NHSN). It is defined as a laboratory-confirmed bloodstream infection (LCBI) where an eligible central venous line was in place for > 2 > 2 > 2 calendar days (with the day of device placement counting as Day 1) on the date of the event or the day before, and the bloodstream infection cannot be attributed to an infection at another anatomical site. CLABSI is intentionally sensitive for hospital quality metrics but lacks specificity for individual bedside clinical management.

Catheter-Related Bloodstream Infection (CRBSI) : A rigorous clinical and microbiological definition established by the Infectious Diseases Society of America (IDSA). It requires definitive microbiological proof demonstrating that the intravascular device is the specific source of the bloodstream infection.

Microbiological Diagnostic Modalities for CRBSI

When line sepsis is suspected, paired blood cultures must be drawn: one set from the catheter hub and one set from a separate peripheral venipuncture site, ensuring equal blood volumes are inoculated into culture bottles. SUSPECTED CATHETER-RELATED SEPSIS

• │
• ┌─────────────────────┴─────────────────────┐
• ▼ ▼
• CATHETER REMOVED CATHETER IN SITU

- Maki roll-plate segment: - Differential Time to Positivity:

• >= 15 CFU on agar plate Catheter flags >= 2 hours
• Quantitative sonication: earlier than peripheral culture

>= 10^2 CFU - Quantitative blood culture:

• Catheter-to-peripheral ratio >= 3:1
• 1. In Situ Diagnostic Criteria (Catheter Maintained)

Differential Time to Positivity (DTP) : Defined as the growth of the identical microorganism in culture bottles inoculated with blood drawn simultaneously from the catheter hub and a peripheral vein, where the catheter-drawn culture flags positive at least 2 hours ( ≥ 2 hours \ge 2\text{ hours} ≥ 2 hours ) earlier than the peripheral culture. A higher bacterial inoculum within the catheter lumen shortens the time required to reach the automated detection threshold. DTP demonstrates high sensitivity ( > 90 % > 90\% > 90% ) and specificity ( > 90 % > 90\% > 90% ) for central line sepsis.

Paired Quantitative Blood Cultures : Considered the reference gold standard. A colony count of the identical organism from the catheter-drawn blood that is ≥ 3 -fold greater \ge 3\text{-fold greater} ≥ 3 -fold greater (ratio ≥ 3 : 1 \ge 3:1 ≥ 3 : 1 ) than the colony count from the peripheral blood confirms CRBSI.

2. Catheter Removal Diagnostic Criteria

Semiquantitative Roll-Plate Method (Maki Technique) : The distal 5 -cm 5\text{-cm} 5 -cm segment of the catheter tip is rolled across a blood agar plate. Growth of ≥ 15 CFU \ge 15\text{ CFU} ≥ 15 CFU indicates significant external catheter surface colonization and potential CRBSI when paired with matching peripheral bacteremia.

Quantitative Sonication Method (Brun-Buisson Method) : Catheter segment is flushed or sonicated in broth to dislodge intraluminal and extraluminal biofilms. Growth of ≥ 10 2 CFU \ge 10^2\text{ CFU} ≥ 1 0 2 CFU ( 100 CFU 100\text{ CFU} 100 CFU ) confirms significant catheter infection.

Indications for Catheter Removal vs. Salvage Protocols

Managing an infected central line requires evaluating the offending pathogen, the presence of local or metastatic complications, and the patient's vascular access anatomy.

Absolute Indications for Immediate Catheter Removal

Prompt line removal is non-negotiable under any of the following circumstances:

High-Virulence / Biofilm Pathogens :

• Staphylococcus aureus (both MSSA and MRSA)
• Candida species (all species)
• Pseudomonas aeruginosa

Multidrug-resistant (MDR) Gram-negative bacilli (e.g., carbapenem-resistant Enterobacteriaceae , Acinetobacter baumannii , Stenotrophomonas maltophilia )

Mycobacterium species and filamentous fungi

Clinical and Structural Complications :

• Severe sepsis or septic shock
• Hemodynamic instability
• Suppurative / septic thrombophlebitis

Tunnel infection (erythema, induration, or tenderness extending > 2 cm > 2\text{ cm} > 2 cm along the subcutaneous tract of a tunneled catheter)

• Subcutaneous port pocket abscess
• Documented endocarditis or metastatic seeding (e.g., septic pulmonary emboli, osteomyelitis)

Persistent bacteremia or fungemia continuing > 72 hours > 72\text{ hours} > 72 hours despite appropriate antimicrobial therapy

Catheter Salvage Exceptions and Antibiotic Lock Therapy

Attempting catheter salvage while administering systemic therapy is acceptable only in highly selected circumstances:

Patients with long-term cuffed tunneled catheters or totally implanted ports who have exhausted vascular access (e.g., end-stage renal disease on hemodialysis, short gut syndrome requiring total parenteral nutrition).

Infection caused exclusively by Coagulase-Negative Staphylococci (CoNS) , such as Staphylococcus epidermidis , or uncomplicated, highly susceptible enteric Gram-negative bacilli (e.g., sensitive Escherichia coli or Klebsiella pneumoniae ).

Patient is hemodynamically stable without evidence of tunnel infection, septic thrombophlebitis, or endocarditis.

Salvage Protocol :

Systemic targeted intravenous antimicrobial therapy for 10 to 14 days.

Antibiotic Lock Therapy (ALT) : Instilling supraphysiological concentrations of antibiotics ( 100 – 1000 × 100\text{--}1000\times 100 – 1000 × the MIC, such as vancomycin 5 mg/mL 5\text{ mg/mL} 5 mg/mL , cefazolin 10 mg/mL 10\text{ mg/mL} 10 mg/mL , or gentamicin 1 – 2 mg/mL 1\text{--}2\text{ mg/mL} 1 – 2 mg/mL ) combined with an anticoagulant (heparin 100 units/mL 100\text{ units/mL} 100 units/mL or sodium citrate) into each catheter lumen during inter-dialytic or dwell periods (typically 8 – 12 hours 8\text{--}12\text{ hours} 8 – 12 hours daily) for 10 to 14 days.

Caution

Catheter salvage must never be attempted for S. aureus or Candida CRBSI, even in patients with limited vascular access. Pathogen-derived extracellular polymeric substances and surface adhesins create irreversible biofilms that resist systemic and lock therapies, resulting in relapse rates exceeding 80 % 80\% 80% , suppurative thrombophlebitis, endocarditis, and significantly increased mortality.

CLABSI Line Removal Decision Matrix

Clinical / Microbiological Scenario Action Regarding Vascular Catheter Systemic Antimicrobial Strategy Key Clinical Rationale

Staphylococcus aureus bacteremia Immediate Removal (MANDATORY) Targeted IV therapy (Cefazolin/Nafcillin for MSSA, Vancomycin/Daptomycin for MRSA) High propensity for endocardial seeding and metastatic abscesses; salvage failure > 80 % > 80\% > 80% .

Candida species fungemia Immediate Removal (MANDATORY) Echinocandin (Anidulafungin, Caspofungin, or Micafungin) Biofilm formation resists sterilization; failure to remove line significantly increases 30-day mortality.

Pseudomonas aeruginosa or MDR GNB Immediate Removal (MANDATORY) Double or targeted antipseudomonal IV therapy based on sensitivities High mortality, rapid tissue destruction, and failure of antibiotic lock eradication.

Tunnel infection or port pocket abscess Immediate Removal (MANDATORY) Systemic IV antibiotics for 7 to 10 days Soft tissue infection outside the lumen cannot be sterilized without surgical hardware explantation.

Septic thrombophlebitis Immediate Removal (MANDATORY) Prolonged IV antibiotics (4-6 weeks) ± \pm ± anticoagulation Infected endovascular thrombus acts as a continuous nidus of bacteremic showering.

Coagulase-negative Staph (stable host, limited access) Catheter Salvage Permitted Systemic IV antibiotics PLUS Antibiotic Lock Therapy (ALT) for 10-14 days Low virulence, lower metastatic risk; preserves critical dialysis or TPN vascular access.

Staphylococcus aureus Bacteremia (SAB) Management

Staphylococcus aureus bacteremia is one of the most treacherous clinical scenarios encountered in critical care. A core clinical axiom is that S. aureus in a blood culture is NEVER a contaminant . In > 98 % > 98\% > 98% of cases, a single positive blood culture bottle represents true bacteremia requiring comprehensive diagnostic workup and complete therapeutic courses.

Mandatory Structured Evaluation of SAB

Serial Surveillance Blood Cultures : Repeat peripheral blood cultures must be obtained every 24 to 48 hours until documented clearance. The first negative blood culture establishes "Day 1" of therapy for calculating treatment duration.

Mandatory Echocardiography : All adult patients with SAB require echocardiographic evaluation to rule out infective endocarditis. Transesophageal echocardiography (TEE) is the definitive gold standard, demonstrating a sensitivity of 95 % 95\% 95% compared to only 50 – 60 % 50\text{--}60\% 50 – 60% for transthoracic echocardiography (TTE). TEE is particularly mandatory in patients with persistent bacteremia, prosthetic heart valves, intracardiac devices, hemodialysis dependence, or physical examination findings of endocarditis.

Identification and Eradication of Metastatic Seeding : SAB frequently metastasizes to vertebral bodies (spondylodiscitis/epidural abscess), spleen, kidneys, and lungs (septic pulmonary emboli). Back pain, persistent fever, or focal neurological deficits warrant emergent spinal MRI.

Antimicrobial Therapy: Beta-Lactam Superiority for MSSA

Methicillin-Susceptible S. aureus (MSSA) :

First-line therapy: Cefazolin ( 2 g 2\text{ g} 2 g IV q8h) or an anti-staphylococcal penicillin ( Nafcillin or Oxacillin 2 g 2\text{ g} 2 g IV q4h).

Critical Board Pearl : Beta-lactams are clinically superior to vancomycin for MSSA. Treating MSSA bacteremia with vancomycin results in a 2- to 3-fold higher rate of treatment failure, relapse, and staphylococcal-attributable mortality due to vancomycin's slower bactericidal killing rate and inferior tissue penetration.

Methicillin-Resistant S. aureus (MRSA) :

First-line therapy: Vancomycin (dosed to achieve AUC 24 / MIC = 400 – 600 mg ⋅ h/L \text{AUC}_{24}/\text{MIC} = 400\text{--}600\text{ mg}\cdot\text{h/L} AUC 24 ​ / MIC = 400 – 600 mg ⋅ h/L ) or Daptomycin ( 8 – 10 mg/kg 8\text{--}10\text{ mg/kg} 8 – 10 mg/kg IV once daily).

When using daptomycin, high doses ( 8 – 10 mg/kg 8\text{--}10\text{ mg/kg} 8 – 10 mg/kg , higher than the FDA-approved 6 mg/kg 6\text{ mg/kg} 6 mg/kg label) are required for bacteremia and endocarditis to prevent emergence of resistance. Baseline and weekly serum creatine phosphokinase (CPK) levels must be monitored to detect daptomycin-induced rhabdomyolysis.

• Uncomplicated vs. Complicated SAB Management Matrix STAPHYLOCOCCUS AUREUS BACTEREMIA
• │
• ┌─────────────────────┴─────────────────────┐
• ▼ ▼
• UNCOMPLICATED SAB COMPLICATED SAB

Must meet ALL criteria: Meets ANY criterion:

• Catheter removed - Persistent bacteremia >72h
• Blood cultures clear within 48-72h - Endocarditis on TEE
• Defervescence within 72h - Prosthetic valve, graft, CIED
• Normal TEE (no vegetations) - Metastatic seeding (discitis, abscess)
• No prosthetic material/devices - Failure to defervesce within 72h
• No metastatic foci │
• │ ▼

▼ TREATMENT DURATION:

• TREATMENT DURATION: 4 to 6 WEEKS IV Therapy
• MINIMUM 14 DAYS IV Therapy
• (from first negative blood culture)
• Catheter-Associated Urinary Tract Infections (CAUTI)

Indwelling urinary catheters are placed in > 20 % > 20\% > 20% of hospitalized ICU patients. CAUTI is one of the most common healthcare-associated infections, yet it represents the single most frequently misdiagnosed and overtreated condition in critical care.

Defining CAUTI vs. Asymptomatic Bacteriuria (ASB)

According to the IDSA guidelines:

CAUTI Definition : Patients with an indwelling urinary catheter (or catheter removed within the preceding 48 hours) presenting with clinical signs and symptoms of UTI with no alternative source, accompanied by significant bacteriuria ( ≥ 10 3 CFU/mL \ge 10^3\text{ CFU/mL} ≥ 1 0 3 CFU/mL of one or more bacterial species in an appropriately collected urine specimen, per IDSA).

Compatible Signs and Symptoms : Fever, rigors, altered mental status, costovertebral angle tenderness, acute flank or pelvic pain, acute hematuria, or systemic sepsis without an identifiable non-urinary source.

The Cardinal Board Rule: Asymptomatic Bacteriuria Must NOT Be Treated

Bacterial Colonization Kinetics : Intraluminal and extraluminal biofilms form along the urinary catheter within 24 to 48 hours of placement. Catheterized patients acquire bacteriuria at a cumulative rate of 3 – 10 % 3\text{--}10\% 3 – 10% per catheter day . Nearly 100 % 100\% 100% of patients catheterized for ≥ 30 days \ge 30\text{ days} ≥ 30 days exhibit chronic bacterial colonization.

Pyuria and Urine Appearance : The presence of pyuria ( > 10 WBC/hpf > 10\text{ WBC/hpf} > 10 WBC/hpf ), cloudy urine, turbid appearance, or strong odor reflects local bladder mucosal inflammatory reaction to the foreign plastic catheter; it does not signify active tissue-invasive infection or clinical pyelonephritis.

Clinical Harms of Overtreatment : Administering antibiotics for asymptomatic bacteriuria does not prevent subsequent CAUTI, does not lower mortality, and does not reduce bacteremia. Instead, it directly promotes Clostridioides difficile colitis, drives selective pressures for carbapenemase-resistant pathogens, and exposes patients to drug toxicity.

Note

There are only two clinical indications where Asymptomatic Bacteriuria (ASB) warrants screening and antimicrobial treatment:

Pregnant women (to prevent pyelonephritis, premature delivery, and low birth weight).

Patients scheduled for invasive urological procedures where mucosal bleeding or trauma is anticipated (to prevent post-procedural bacteremia and urosepsis).

In all other ICU and hospitalized patients—including those with diabetes, elderly patients, spinal cord injuries, or neutropenia without symptoms—treating ASB is strongly contraindicated.

Management of Confirmed CAUTI

Catheter Removal or Exchange : If the indwelling catheter has been in place for ≥ 7 – 14 days \ge 7\text{--}14\text{ days} ≥ 7 – 14 days and urinary drainage remains clinically necessary, the existing catheter must be removed and a new catheter placed prior to collecting a urine culture and initiating antimicrobial therapy. Culturing urine from an old catheter samples intraluminal biofilm rather than bladder urine.

Antimicrobial Duration :

7 days of targeted antibiotics for patients who experience prompt clinical improvement and defervescence.

10 to 14 days for patients with delayed clinical response, structural urinary tract abnormalities, or associated secondary bacteremia.